arrow
R

Robert W. Simms

Boston University
H指数:59
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

联合使用吡非尼酮与霉酚酸酯治疗系统性硬化症相关性间质性肺疾病(硬皮病肺研究III):一项研究者发起的、多中心、随机、双盲、安慰剂对照的2期临床试验

2025-11-260
OAAI
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial

自体非清髓性造血干细胞移植治疗弥漫性皮肤系统性硬化症:前瞻性、单臂试验中识别毒性及长期结局的疾病危险因素

2025-01-140
OAAI
Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data
2022-11-166
OA
Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial
2022-06-2718
OAAI
Reply
2021-02-181
PREAI
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
2020-12-0129
OAAI
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
2019-12-10170
OAAI
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis

肺动脉高压风险的遗传决定因素: 国际全基因组关联研究和荟萃分析

2019-03-01128
OAAI
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry
2018-10-0126
PREAI
Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis
2018-04-0136
OAAI
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
2018-01-04413
OAAI